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ABSTRACT. We have previously demonstrated that N-benzylaminoferrocene-based prodrugs 
are activated in the presence of the cancer-specific levels of reactive oxygen species (ROS) and 
are toxic towards several cancer cell lines and primary cells, but non-toxic to representative 
normal cells (Marzenell, P. et al, J. Med. Chem., 2013, 56(17), 6935; Hagen, H. et al, J. Med. 
Chem., 2012, 526(2), 924). Herein we report on a substantially improved method of synthesis of 
these compounds with a yield of up to 90 %. We demonstrate its applicability by preparing nine 
new aminoferrocenes and scaling up successfully the synthesis of the most active prodrug 4 (4-
(N-ferrocenyl-N-benzylaminocarbonyloxymethyl)-phenylboronic acid pinacol ester) up to 2 g, 
which was required for further in vivo experiments reported in this paper. Next, we studied the 
effects of aminoferrocenes on the viability of selected cancer cell lines (JVM-2, RAJI, BL-2 and 
HL-60) and primary chronic lymphoid leukemia (CLL) cells having different p53 status (wild 
type, mutated or completely absent). The obtained data were in agreement with the hypothesis 
that the toxicity of aminoferrocenes is not dependent upon p53 status. Subsequently the toxicity 
of prodrug 4 was investigated ex vivo using rat precision cut liver slices (PCLS). Interestingly, 
prodrug 4 was found to exhibit substantial toxicity (IC50= 3.8 + 1.3 µM) in freshly prepared 
PCLS, which initially contained a low amount of glutathione (GSH). In contrast, it was found to 
be non-toxic up to the highest tested concentration (10 µM) in PCLS pre-incubated for 24 h, that 
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contained a normal GSH amount. Since this low amount of GSH is likely to correlate with a high 
intracellular oxidation state, these data are in agreement with the reported mode of activation of 
aminoferrocenes. In addition, we demonstrated that intraperitoneal administration of a single 
dose of up to 6 mg/kg of prodrug 4 does not affect the weight and the survival of hybrid male 
mice BDF1 (DBA/2,♀ x C57Bl/6, ♂) for at least 21 days after injection. Finally, in a preliminary 
in vivo experiment prodrug 4 was shown to extend the survival of hybrid male mice BDF1 
carrying L1210 leukemia from 13.7 + 0.6 days to 17.5 + 0.7 days when injected daily for 6 times 
at a dose of 26 µg/kg (cumulative dose: 0.156 mg/kg) starting from the second day after injection 
of L1210 cells. We confirmed that the antitumor activity of prodrug 4 correlates with the 
increase of the oxidative stress in L1210 cells isolated from treated animals, which is reflected in 
the higher intracellular ROS concentration and damage of the cellular membrane. All together 
our data indicate that aminoferrocene-based prodrugs can potentially be applied for the treatment 
of cancers, which express mutated or no p53 and are often poorly responsive to the conventional 
chemotherapy. 
 
INTRODUCTION 
The intracellular milieu of cancer cells differs substantially from that of normal ones. This 
difference can be utilized to design cancer specific, ROS-sensitive prodrugs.
1
 In particular, the 
concentration of reactive oxygen species (ROS= 
1
O2, O2
-
, H2O2, HO•) is higher in the majority 
of cancer cells.
2
 It has been suggested that this biochemical alteration is required to support the 
cancerous phenotype. Therefore, designing prodrugs that need activation by ROS can lead to 
anti-cancer drugs that are active against a broad range of cancers.
3
 Known prodrugs activated at 
elevated ROS concentrations include the naturally occurring cyclic glycopeptide bleomycin,
4
 
 4 
hydroxyferrocifen and its analogues,
5
 organochalcogene-based pro-catalysts,
6
 H2O2-responsive 
pro-alkylation agents,
7
 SN-38 (a camptothecin derivative)
8
 and aminoferrocene-based prodrugs.9 
In particular, bleomycin coordinates intracellular iron ions (present in excess in cancer cells) 
resulting in the formation of a potent catalyst for cleavage of genomic DNA.
4
 
Hydroxyferrocifens and organochalcogenes are oxidized to glutathione (GSH) scavengers and 
ROS-generating catalysts, respectively; thus, inducing cell death via oxidative stress.
5,6
 
Furthermore, pro-alkylating agents, such as SN-38 and aminoferrocenes are activated by the 
cleavage of a C-B bond in the presence of cancer-specific H2O2 concentrations.
8,9
 In the case of 
aminoferrocenes two toxic products are obtained, one of them being a ROS-generating catalyst 
and the other a GSH scavenger. These products act synergistically on each other leading to a 
strong elevation of ROS concentration in cancer cells causing their death. The dual mode of 
action of aminoferrocenes is unique.
9
 The only other drug reported up to date, acting by a related 
mechanism, is [(6-arene)Ru(azpy)I]+.10 In particular, this compound first oxidizes GSH to 
GSSG. Then, the reduced complex is oxidized by O2 to give the initial complex and H2O2. 
However, in contrast to aminoferrocenes this compound is not a prodrug. Therefore, it can 
potentially affect also normal cells. Moreover, the oxidized product (GSSG) can be recovered by 
intracellular reductases thereby diminishing the effect of the drug. In contrast, products released 
from aminoferrocenes irreversibly modify glutathione by alkylating it.
9
  
In previous work we have demonstrated that selected aminoferrocenes are active against 
primary chronic lymphoid leukemia (CLL) cells,
9b
 However, in this preliminary study the 
genetic status of CLL cells was not determined. Nevertheless, it is well documented that CLL is 
a genetically heterogeneous disease and some CLL-types exhibit poor prognosis.
11
 For example, 
TP53-mutated CLL is poorly responsive to standard therapy. The TP53 gene encodes tumor 
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suppressor p53, a protein participating in cell cycle regulation. Therefore, search for new drugs 
for the treatment of TP53-mutated CLL and other hematological cancers is warranted. Since the 
mode of action of aminoferrocenes relies on ROS-induced chemical activation that is not directly 
related to TP53,
9
 it is probable that these prodrugs will be active against both wild type and TP53 
mutated/negative hematological cancers. Herein, we discuss a new series of data proving this 
hypothesis using three B-cell derived cancer cell lines with different TP53-status and primary 
CLL cells with defined TP53 status. Moreover, we report on studies of toxicity and antitumor 
activity of a selected aminoferrocene (compound 4, Scheme 1) using rat precision cut liver slices 
(ex vivo), and BDF1 (DBA/2,♀ x C57Bl/6,♂) mice carrying TP53-mutated L1210 leukemia (in 
vivo). For these biological experiments a large amount of prodrug 4 (up to 2 g) was required, 
which was obtained using a substantially improved method of synthesis of N-benzylated 
aminoferrocenes. We also demonstrated the general applicability of this method by preparing 
nine new N-substituted aminoferrocenes.    
           
RESULTS AND DISCUSSION 
Synthesis of N-alkylated aminoferrocene-based prodrugs   
The previously reported procedure for preparation of compound 4 yielded under optimized 
conditions only ~5 % of the product.
9
 It consisted of reductive amination of commercially 
available aminoferrocene 1 in the presence of benzaldehyde and Na[B(CN)H3] with formation of 
N-benzylaminoferrocene 2,  followed by coupling of compound 2 to 4-
(hydroxymethyl)phenylboronic acid pinacol ester in toluene in the presence of triphosgene at 120 
°C for 24 h (steps a, b in Scheme 1). Since the intermediate product 2 is unstable in air, these two 
 
 6 
Scheme 1. Outline of tested pathways for optimization of synthesis of N-alkylated 
aminoferrocene-based prodrugs  
 
a: RR’C=O, NaB(CN)H3; b: 4-hydroxymethylphenylboronic acid pinacol ester, 
Cl3COC(O)OCCl3, 120 °C;
9
 c: same as b; d: benzyl chloride, Cs2CO3, tert-butylamonium iodide 
(TBAI); e: 1,2-di-(chloromethyl)benzol, Cs2CO3, TBAI; f: compound 3, Cs2CO3, TBAI. 
 
steps were conducted in a one pot reaction. We observed that changes of conditions including (1) 
optimization of the reductive amination combined with isolation of compound 2, (2) replacement 
of triphosgene either for N,N’-carbonyldiimidazole (CDI) or CDI/CH3I mixture or 4-
nitrophenyloxycarbonylchloride and (3) increasing nucleophilicity of the hydroxyl group of 4-
hydroxymethylphenylboronic acid pinacol ester by its deprotonation on the presence of NaH led 
to further reduction of the yield of the desired product. Moreover, application of substituted 
benzaldehydes in this reaction sequence with an attempt to prepare analogues of compound 4 
was hampered by even lower yields. The latter effect was especially pronounced for 
pyridinecarboxaldehydes and 2- and 4-substituted benzaldehydes carrying either electron 
donating substituents like OMe, NMe2 or CH3 or thermally and hydrolytically unstable  
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substituents like OAc or NHAc. Therefore, an alternative approach for synthesis of compound 4 
was developed. In particular, we used compound 3 as a starting material. In contrast to 2, 
compound 3 is highly stable and can be obtained from commercially available starting materials 
in large quantities with 74 % yield.
9a
 We attempted alkylation of compound 3 (1) under 
optimized Mitsunobu conditions for carbamates,
12
 using benzyl alkohol, Bu3P and 1,1’-
(azidodicarbonyl)dipiperidine (ADDP); (2) in the presence of Cs2CO3 using BnCl/(NBu4)I 
mixture as an electrophile under conditions of Salvatore et al
13
; and (3) in the presence of NaH 
using either benzyl chloride or bromide as electrophiles as described elsewhere for other starting 
materials.
14
 Though the first approach delivered only traces of the product, the other two reaction 
conditions led to clean conversion of compound 3 into 4. Isolated yields of analytically pure 
compound 4 varied in the range between 71 and 92 %, which is substantially improved with 
respect to the previously reported synthetic protocol (5 %). We confirmed that this method is 
suitable for scaling up the synthesis of compound 4 up to 2 g. We also used this protocol to 
prepare nine new analogues of 4, including compounds, containing differently substituted 
phenylmethyl and pyridylmethyl moieties. In particular, in the series of compounds 4, 5, 6 
electron deficiency of the Ph-rest is modulated by substituents in the 3
rd
 position: H, F, OMe. In 
compound 7 the para-hydroxy group is protected as an acetic acid ester. In cells it is expected to 
be deprotected via hydrolysis forming the highly electron rich 4-hydroxyphenylmethyl-
containing aminoferrocene, which will be partially deprotonated at pH 7 with formation of the 
phenolate ion (pKa ~ 9-10). In contrast, 2- and 3-pyridyl-residues in compounds 8 and 9 are 
strongly electron deficient. At pH 7 they are expected to remain neutral (pKa~ 5-6). Compound 
10 is derived from 4 by substitution of a benzyl for a diphenylmethyl residue. It is obtained by 
alkylation of intermediate 3 with diphenylmethylchloride with the relatively low yield of 6 %. 
 8 
The latter result reflects the low reactivity of the corresponding electrophile due to its steric 
bulkiness. Compound 10 is the first example of the aminoferrocene-based prodrug where the 
carbon atom connected to the nitrogen atom of the aminoferrocene core carries two substituents 
(phenyl residues in this case). Synthesis of such derivatives using the initially applied protocol 
was not possible since the reductive amination product formed from aminoferrocene 1 and 
ketones in step a is not reactive in the following step b (Scheme 1). Since all steps in the new 
protocol were conducted at 22 °C, thermally unstable or reactive substrates could be applied. For 
example, compound 11, which carries 2-chlormethyl residue could be prepared from equimolar 
mixture of compound 3 and 1,2-di(chlormethyl)benzene. The product was isolated with the yield 
of 34%. X-ray single crystal diffraction analysis allowed to determine the structure of compound 
11 (Figure 1), which is the first crystallographically characterized aminoferrocene-based  
 
Figure 1. Molecular structure of compound 11 as determined by X-ray crystallography.  
 
prodrug. These data confirm the atom connectivity suggested based on the synthesis, 
1
H NMR 
spectroscopy and mass spectrometry of 11. The geometry of a ferrocene unit in compound 11 is 
similar to that in other known alkyloxycarbonylaminoferrocenes.
15
 Atoms of a carbamate group 
 9 
(C2, N1, C3, O1, O2) are located in a plane, which is inclined by 24° to the plane of the 
cyclopentadienyl ligand containing atoms C42, C41 and C45 (Figure 1). These data are 
indicative of only weak conjugation between the ferrocene unit and the carbamate fragment. The 
fully planar conformation is not realized due to the expected clash between the bulky substituents 
at N1 atom with the hydrogen atoms attached to C42 and C45 atoms. It is evident that a fragment 
–H2C1-Cl1 is not hindered by other atoms in structure 11 (Figure 1). Therefore, we expected that 
it is accessible to nucleophilic reagents. In agreement with this expectation, we observed that 11 
reacts with excess 3 with formation of doubly substituted product 12. We are currently exploring 
11 for conjugation of the aminoferrocene core to other nucleophilic modifiers, e.g. those, which 
can either target these prodrugs to specific compartments in cells (e.g. nuclei or mitochondria) or 
direct them to cancer cells. Analogously to mono-aminoferrocene-based compound 3, 1,1’-bis-
aminoferrocene-based compound 13 can be efficiently alkylated at the optimized conditions 
producing doubly N-benzylated product 14 with the yield of 55 % (Scheme 2). In this case the 
yield is slightly lower than that observed in the alkylation of compound 3 – 71-92 %.  
Thus, the synthetic method described above expands our possibilities in the modification of the 
N-substituent in aminoferrocenes at the sites indicated with red arrows in Scheme 1, whereas the 
previously used protocol allowed only modifications at the sites indicated with blow arrows and 
was restricted to thermally stable substrates. Moreover, it allows scaling-up the synthesis of N-
substituted aminoferrocenes that enables their thorough structural, spectroscopic and biological 
studies. 
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Scheme 2. Synthesis of doubly-modified aminoferrocenes using the developed improved 
synthetic protocol and structures of controls.  
 
a: BnCl, Cs2CO3, TBAI. 
 
Effects of prepared prodrugs on the viability of B-cell-derived cancer cell lines having 
different TP53-status 
To explore the role of p53 in the mode of action of aminoferrocene-based prodrugs we studied 
their effects on the viability of three selected B-cell derived cancer cell lines with different TP53 
status. The human mantle cell lymphoma (MCL) was represented by the JVM-2 cell line. MCL 
accounts for ~7 % of all lymphoid malignancies and has relatively poor prognosis due to almost 
invariable relapse occurring after initial chemotherapy.
16
 The JVM-2 cell line contains wild type 
(wt) p53 and an additional t(11;14) translocation. The human Burkitt lymphoma was represented 
in our panel by RAJI and BL-2 cell lines. Notably, mutated p53 is expressed in RAJI, whereas wt 
p53  in BL-2 cells. Moreover, in RAJI a translocation t(8,14) as well as Epstein-Barr-Virus 
(EBV+) are detected, whereas in BL-2 a translocation t(8,22) is present. The latter cell line is 
EBV negative.
17
 The promyelocytic human leukemia cell line HL-60, which expresses no 
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detectable p53 protein and p53 mRNA and whose TP53 gene underwent major deletions,
18
 was 
also included for comparison (Table 1). 
First, we determined the relative amounts of intracellular reactive oxygen species in JVM-2, 
RAJI and BL-2 by using 2,7-dichlorodihydrofluorescein diacetate (DCFH-DA)-based assay as 
described earlier.
9
 In particular, we observed that the relative mean fluorescence (F) of JVM-2 
(F= 0.71 + 0.01) or BL-2 cells (F= 0.77 + 0.03) measured after their incubation with DCFH-DA 
for 30 min was comparable to that of HL-60 cells (F=1.0). In contrast, in these conditions the 
relative mean fluorescence of RAJI cells was ~3 fold higher than that of HL-60 cells. These data 
indicate that ROS amounts in JVM-2 and BL-2 cells are similar to that in HL-60 cells, whereas 
in RAJI cells it is higher than that in HL-60 cells. Since the prodrugs are efficiently activated in 
HL-60 cells due to their reaction with ROS,
9
 these data indicate that an analogous activation 
should  also be possible in JVM-2, BL-2 and RAJI cells provided that the prodrugs are taken up 
into the cells.  
The physiological concentration of boron-containing compounds in cells is negligible. Since 
each molecule of the prodrug contains one boron atom, we could investigate the membrane 
permeability of these compounds by monitoring the boron content in the cells.
9
 Intracellular 
boron was determined for all four studied cell lines by the curcumin assay in combination with 
UV-visible spectrophotometry for the representative compound 4. In this assay the uptake 
correlates with the baseline corrected absorbance at 550 nm (A(550 nm) − A(780 nm)) 
characteristic for the curcumin-boron complex. In particular, untreated cells give rise to A(550 
nm) − A(780 nm) in the range of 0.34-0.38, whereas cells incubated with compound 4 give rise 
to A(550 nm) − A(780 nm) between 1.30 and 2.36. When the uptake of compound 4 in HL-60 
cells is taken as a reference (1.0), the permeability in RAJI cell line  
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Table 1. Effects of the aminoferrocene-based prodrugs on the viability of the selected cell lines 
(IC50 values) with different p53-status after 48 h incubation.
i 
Drug
ii
 IC50 (µM) 
HL-60 
no p53 
RAJI 
mut p53 
BL-2 
wt p53 
JVM-2 
wt p53 
3 >50 >50 >50 ~50 
4 11 + 1 35 + 6 25 + 1 29 + 6 
5 9 + 7 36 + 5 23 + 5 30 + 4 
6 17 + 4 36 + 2 23 + 7 30 + 4 
7 16 + 1 37 + 3 26 + 0 37 + 5 
8 ND >50 19 + 3 41 + 7 
9 ND >50 21 + 6 45 + 5 
10 15 + 2 21 + 4 16 + 1 24 + 6 
11 6 + 0 7 + 1 3.8 + 0.4 8 + 0 
12 ~50 >50 >50 >50 
13 8 + 8 ND ND ND 
14 10 + 0 >50 29 + 19 >50 
15 >50 >50 >50 >50 
16 >50 >50 >50 >50 
17 3 + 1 3 + 1 3 + 1 3 + 1 
i
 no p53 – wt p53 is not expressed; mut p53 – mutated p53; wt p53 – active (wild type) p53 is 
expressed. Data are given as mean of at least three independent experiments + SD. ND – not 
determined. 
ii
 Structure of prodrugs and their labeling scheme are given in Schemes 1 and 2.  
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can be determined to be equal to 1.8 + 0.5, that in JVM-2 cell line to be 1.5 + 0.1 and that in BL-
2 cell line 1.4 + 0.1. These data indicate that, within the experimental error, compound 4 
permeates equally well through the membranes of all studied cell lines.       
Furthermore, we studied the viability of three selected B-cell derived cancer cell lines and of HL-
60 cell line in the presence of known (3, 4, 13) and newly prepared aminoferrocene-based 
prodrugs by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assay (Table 1). Among the new aminoferrocenes reported in this paper, only compound 11, 
which contains a 2-CH2Cl residue in the N-benzyl substituent, turned out to be substantially 
more toxic towards all cell lines tested than the parent compound 4 (p< 0.01). We can speculate 
that in this case the stronger cytotoxic effect could be caused by alkylation of endogenous 
nucleophilic moieties, e.g. thiol groups of GSH or proteins, by the 2-CH2Cl residue. At this point 
other possible mechanisms, e.g. enhanced uptake of this compound, cannot be excluded. Since 
the experiments with the CLL cells (as described below) were performed with medium 
containing human serum (HS), whereas the cell lines were incubated in medium with fetal calf 
serum (FCS), we investigated whether the replacement of FCS by HS in experiments with HL-60 
cells affects the toxicity of compound 11 as well as that of reference compound 4. We observed 
that while the effect of compound 4 was not dependent on the type of the serum used, the 
toxicity of 11 was fully inhibited in the HS-containing medium even at the highest concentration 
of the drug used (50 µM). Furthermore, in experiments with CLL cells compound 11 exhibited 
no toxicity at concentrations of up to 10 µM (data not shown). These data indicate that HS is able 
to scavenge in some way compound 11. Since the only structural difference between compounds 
4 and 11 is the presence of a strongly electrophilic CH2Cl group in the latter case, we can suggest 
that the scavenging occurs due to alkylation of nucleophilic centers of HS by compound 11. 
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Independent of the mechanism of the latter process, it may preclude the possible anticancer 
activity of compound 11 in vivo. Therefore, this prodrug was not selected for further biological 
tests.  
It is worth noting that neither the substitution of 3- and 4-H-atoms in the phenyl residue for 
either electron donating or accepting moieties (compounds 5, 6, 7) nor the replacement of the 
phenyl rest with 2- and 3-pyridyl moieties (compounds 8, 9) affected the activity of 
aminoferrocenes substantially. Furthermore, substitution of the N-benzyl residue for N-
diphenylmethyl (compound 10) only slightly enhanced the activity towards the cancer cell lines 
RAJI (IC50= 21 + 4 µM for 10 versus 35 + 6 µM for 4, p<0.05) and BL-2 (IC50= 16 + 1 µM for 
10 versus 25 + 1 µM for 4, p<0.01), whereas its effect on two other cell lines (HL-60 and JVM-
2) was found to be negligible (Table 1). Unfortunately, the N-benzylation of the carbamate group 
of a 1,1’-bis-aminoferrocene-derived prodrug did not exhibit the analogous favorable effect as 
the same derivatization of the mono-aminoferrocenes (compare 13, 14 and 3, 4, Table 1).  
We observed that the resistance of wt p53-expressing BL-2 and JVM-2 cell lines as well as mut 
p53-expressing RAJI cell line towards aminoferrocenes is similar for the majority of the 
prodrugs studied here, except that in a few cases (compounds 7, 8 and 9) the BL-2 cell line was 
found to be slightly more sensitive than RAJI and JVM-2 cell lines (Table 1). Overall, these data 
support the hypothesis that the anticancer activity of aminoferrocene-based prodrugs does not 
require p53 activity.  
Effect of aminoferrocenes on the viability of wild type and TP53-mutated/deleted chronic 
lymphocytic leukemia cells  
Subsequently, we investigated the effects of two representative aminoferrocene-based prodrugs 
3 and 4 on the viability of CLL cells isolated from 25 patients. In this group 8 patients had p53-
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mutated CLL cells and 17 patients had wild type p53 CLL cells.  The effect of compounds 3 and 
4, as well as of fludarabine on the viability of CLL cells was determined by using ATPlite™ 
Luminescence Assay System (PerkinElmer, Waltham, USA). Fludarabine is a purine analogue, 
which is currently used as a standard treatment of the CLL disease. The mode of action of this 
drug depends upon p53,
19
 making it more active against wt p53 cancer types. Therefore, 
treatment of CLL patients with fludarabine can cause a selective survival of p53-mutant CLL 
cells, which are more resistant and, therefore, less responsive to the therapy. We observed that 
after treatment of p53-mutated CLL cells (8 patients) with fludarabine (10 µM) for 48 h 48.7 + 
16.1 % viable cells remained in the suspension, whereas the same treatment of wild type p53 
CLL reduced the number of viable cells to 34.7 + 18.1 % (17 patients, Figure 2).  
 
Figure 2. Mutated p53 CLL cells (mut TP53, 8 patients) or wild type CLL cells (wt TP53, 17 
patients) were treated with prodrugs 3, 4 or fludarabine (each 10 µM) for 48 h and the % of 
viable cells in suspension was determined as described in the experimental section and plotted as 
the relative number of viable cells (the total number of control untreated cells was taken as 100 
%).   
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The response of the cells of the selected, small group of patients to fludarabine was strongly 
heterogeneous, which is reflected in large standard deviations of the number of viable cells in 
populations of treated CLL cells – 16.1 % for p53-mutated CLL and 18.1 % for wild type p53 
CLL. Therefore, the difference in activities of this drug towards mut p53 CLL and wt CLL cells 
observed is not significant within the observed experimental error (Student’s t-test).   
Aminoferrocenes 3 and 4 exhibited in general a higher toxicity towards CLL cells than 
fludarabine (p<0.001): 9.1-12.5 % viable cells left after their treatment with these prodrugs (10 
µM) for 48 h (compare with 39.2 % obtained after the treatment of CLL cells with fludarabine). 
Their toxicity turned out to be practically independent of the status of p53 in CLL cells (Figure 
2). These data are in agreement with our results obtained for B-cell-derived cell lines (see above) 
and support the hypothesis that the mode of action of aminoferrocenes is not dependent upon 
p53. This advantageous property can make these prodrugs potentially suitable for the treatment 
of p53-mutated CLL and other hematological cancers. 
 
Ex vivo and in vivo toxicity of aminoferrocene 4 
Based on the preliminary studies obtained so far, we selected compound 4 for further 
evaluation of its toxicity ex vivo and in vivo. We have previously shown that this prodrug is not 
toxic towards normal (non-cancer) cells including fibroblasts (< 100 µM) and primary 
mononuclear cells (MNC’s, < 10 µM).9 In order to validate these in vitro data in a more complex 
experimental model, we first investigated the toxicity of compound 4 ex vivo using rat precision-
cut liver slices (PCLS) according to established procedures.
20
 PCLS are viable explants of tissue 
with a reproducible and well-defined thickness, containing cells in their natural environment. 
Notably, this technique is an FDA-approved model for drug toxicity and metabolism studies, and 
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it has been applied already for the assessment of toxicity of cisplatin
21
 and experimental gold-
based compounds.
22
 In this assay liver cells remain in their natural environment and therefore, 
the obtained toxicity results are expected to be more relevant than those obtained earlier in 
experiments with cell cultures.  
Thus, rat liver slices were cut and pre-incubated either for 1 h or 24 h before exposure to the 
prodrug as detailed in the experimental section, to allow the cells to recover from the cold 
ischemia and the slicing procedure. After pre-incubation, slices were incubated in fresh WEGG 
medium containing 2.5 µM, 5 µM or 10 µM of compound 4 for a period of 24 h. Afterwards 
they were collected and the viability of the tissues was determined measuring the ATP content. 
The choice of the pre-incubation time appeared to be  crucial: A marked decrease in the viability 
of 1 h pre-incubated slices was already found at a concentration of 5 µM prodrug (Figure 3). In 
contrast, slices pre-incubated for 24 h remained practically fully viable (83 %) even at the 
highest tested concentration (10 µM, Figure 3).  Since aminoferrocenes are activated and as such 
expected to be more toxic under oxidative conditions
9
, we may speculate that after 1 hour pre-
incubation the slices are subject to oxidative stress due to the organ excision and slicing 
procedure increasing their sensitivity to compound 4. Indeed, others have reported that shortly 
after slice preparation the GSH concentration in the slices is low.
23
 In contrast, after 24 h pre-
incubation slices reach a more physiological equilibrium, which is reflected in normal 
intracellular GSH concentration.
23
 Preliminary experiments exploring the toxicity of cisplatin in 
liver slices have shown that no effect of pre-incubation exists for this compound (data not 
shown). This indicates that the effect of pre-incubation is probably related to the specific toxic 
mechanism of aminoferrocenes. Taken together these data confirm that in normal (non-
malignant) cells, which are characterized by low ROS concentration, aminoferrocenes remain 
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inactive.
9
 Furthermore, experiments were carried out with ferrocene 15 as a negative control and 
17 as a positive control (Scheme 2). Both compounds were added to slices pre-incubated for 24 
h, and incubation was continued for additional 24 h. As expected, ferrocene 15 showed no 
reduction in viability even at 40 µM, whereas compound 17 showed a high toxicity with an IC50 
of ca. 1 µM. 
Based on the promising in vitro
9
 and ex vivo data on the toxicity of prodrug 4, we decided to 
further study its effects on healthy hybrid male mice BDF1 (DBA/2,♀ x C57Bl/6, ♂) at variable  
 
Figure 3. Viability of precision cut liver slices (PCLS) after 24 h of incubation with the 
aminoferrocene-based prodrug 4 and positive control 17 following 1 h (1 h pre) or 24 h of pre-
incubation (24 h pre). 
doses between 10 and 6000 µg/kg as described in the experimental section. Each dose was 
introduced via an intraperitoneal injection. One group contained 6 animals, which were 
monitored for 21 days after the drug injection. Every third day animals were weighted. All 
animals survived this treatment. Their weight increased by 1.8-2.5 g during the time of the 
experiment. The same weight increase was observed in the control group, which received no 
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treatment. These data suggest that prodrug 4 exhibits no fulminant toxicity in vivo at 
concentrations of up to 6 mg/kg, although more subtle effects cannot be excluded.     
 
Antitumor activity of prodrug 4 in vivo  
Finally, antitumor activity of 4 was evaluated on hybrid male mice BDF1 (DBA/2,♀ x 
C57Bl/6, ♂), which carry L1210 leukemia, expressing mutant p53.17 In an exploratory 
experiment the treatment of mice (15 animals per group) was started on the second day after 
injection of L1210 cells. It included six daily intraperitoneal injections of compound 4 at a dose 
of 26 µg/kg in PBS solution (0.5 mL) containing 0.2 % (v/v) DMSO (total dose: 0.156 mg/kg). 
The control groups received the same volume of PBS solution. We observed that survival of the 
mice was extended from 13.7 + 0.6 days in the control group to 17.5 + 0.7 days in the treated 
group (p<0.05). This corresponds to 28 % lifetime extension that according to Sofina et al
24
 
indicates a significant antitumor effect thereby justifying further investigations of prodrug 4. It 
has been previously reported that 7 days after intraperitoneal injection of L1210 in BDF1 mice 
(DBA/2,♀ x C57Bl/6, ♂) ascites fluid of the animals contains over 93 % of L1210 cells with 
respect to the total cell number.
25
 In order to evaluate the drug-induced oxidative stress, we took 
probes of ascites fluid of treated and control groups and analyzed mitochondria integrity (JC-1 
assay) and the intracellular ROS amount (CM-H2DCF DA assay) in the L1210 cells that were 
present in this sample. In particular, the fluorescence of L1210 cells isolated from the drug-
treated animals and incubated with the JC-1 probe was found to be 97.0 + 4.3 arbitrary units 
(a.u.), whereas the control probe (cells isolated from untreated animals) exhibited significantly 
(p<0.05) lower fluorescence of 48.2 + 3.1 a.u. These data indicate the disturbance of the function 
of mitochondria in the cancer cells in the treated animals. Furthermore, we observed that L1210 
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cells from the treated animals, which were incubated with CM-H2DCF DA dye (230.0 + 18.5 
a.u.), were more fluorescent than those from the control group (163.3 + 20 a.u., p< 0.05). These 
data indicate that the treatment with compound 4 enhances the oxidative stress in cancer cells in 
vivo.         
 
CONCLUSIONS 
We developed a substantially improved method for synthesis of N-substituted aminoferrocene-
based prodrugs, which leads to yields of 72-91 %. In contrast, by using the previous method 
these compounds could be obtained with yields of under 5 %.
9
 In the key step, easily accessible 
starting material 4-(ferrocenylaminocarbonyloxymethyl)-phenylboronic acid pinacol ester was 
alkylated by variable benzyl chlorides or bromides at 22 °C, whereas in the previously used 
protocol prolonged heating at 120 °C was required.
9
 Therefore, heat sensitive building blocks 
could be introduced by the new approach, including for example an N-(4-
acetyloxyphenyl)methyl substituent. Overall, nine new N-substituted prodrugs were prepared by 
this protocol, which were obtained in high purity and amount and required limited purification. 
Thus, we were able to characterize the biological effects of the new series of compounds in vitro, 
ex vivo and in vivo. First, we observed that the prodrugs exhibit similar toxicity towards B-cell 
derived hematological cancer cell lines (JVM-2, RAJI and BL-2) having different p53 status. 
Subsequently, we confirmed that the toxicity of aminoferrocenes is practically independent from 
the p53 status in primary CLL cells. In preparation to the in vivo studies of the antitumor activity 
of the prodrugs, we confirmed that compound 4 exhibits practically no toxicity up to 10 µM in 
precision cut liver slices pre-incubated for 24 h up (ex vivo), and up to 6 mg/kg in hybrid male 
mice BDF1 (DBA/2,♀ x C57Bl/6, ♂) (in vivo). Finally, the antitumor activity of the most active 
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prodrug 4 was studied in hybrid male mice BDF1 (DBA/2,♀ x C57Bl/6, ♂), which carry L1210 
leukemia. We observed that compound 4 administered in 6 daily doses of 26 µg/kg extends the 
survival of the mice from 13.7 + 0.6 days to 17.5 + 0.7 days. The prolonged survival was 
accompanied by increased oxidative stress of and membrane damage in L1210 cells isolated 
from the ascites fluid of treated animals. It is worth mentioning that the dose used in the in vivo 
antitumor experiment is much lower than the maximum texted dose of the in vivo toxicity 
studies, where no weight loss of the animals has been observed. Although further studies are 
necessary to validate the mechanisms of action of this new class of compounds, as well as more 
advanced toxicity studies, our findings indicate that these aminoferrocene prodrugs can 
potentially be applied for the treatment of cancers, which express mutated or no p53 and are 
often poorly responsive to the conventional chemotherapy. 
 
EXPERIMENTAL SECTION 
General Information 
Commercially available chemicals of the best quality from Aldrich/Sigma/Fluka (Germany) were 
obtained and used without purification. Starting materials 1-3 (Scheme 1), 13 (Scheme 2) and 
control compounds 16 and 17 (Scheme 2) were prepared as described previously.9 NMR spectra 
were acquired on a Bruker Avance 400 or Bruker Avance III 600 spectrometer. ESI mass spectra 
were recorded on a Bruker ESI MicroTOF II. C, H, and N analysis was performed in the 
microanalytical laboratory of the chemical institute of the Fiedrich-Alexander-University of 
Erlangen-Nürnberg. UV-vis spectra were measured on a Lambda Bio+ UV/Vis 
spectrophotometer (Perkin Elmer) by using quartz glass cuvettes (Hellma GmbH, Germany) with 
a sample volume of 1 mL or micro-cuvettes with a sample volume of 100 µL (BRAND GmbH, 
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Germany). The fluorescence of live cells was quantified using a Guava easyCyteTM 6-2L Flow 
cytometer from Merck Millipore. The data were processed using the inCyteTM software package 
from Merck Millipore and the ModFIT LTTM software from Verity Software House.  The purity 
of the prodrugs used in the biological tests was determined by C, H, and N analysis. According 
to these data, the purity of the prodrugs and controls was greater than 95%. Crystal structure data 
for prodrug 11 (Figure 1) were submitted to the Cambridge Structural Database (CSD). This 
structure was assigned the deposition number CCDC 1011896. 
 
Synthesis 
Compound 4, protocol 1. Compound 3 (0.5 g, 1.08 mmol) was dissolved in anhydrous DMF (20 
mL) under nitrogen atmosphere. Then Cs2CO3 (1.06 g, 3.25 mmol) and tetra-butylammonium 
iodide (TBAI, 1.20 g, 3.25 mmol) were added to the solution. After stirring for 30 minutes at 22 
°C, benzyl chloride (412 mg, 374 µL, 3.25 mmol) was added. The mixture was stirred for 18 h at 
22 °C. Then, the solvent was removed in vacuum (0.01 mbar) and the product was purified by 
column chromatography on silica gel using petroleum ether/acetone (10/1, v/v) as eluent yielding 
an orange oil. Triturating of this material with hexane gave the product as an orange solid. Yield: 
427 mg, 0.77 mmol (71%). TLC (SiO2, eluent petroleum ether/acetone, 4:1, v/v) Rf = 0.5; 1H-
NMR (aceton-d6, 300 MHz) δ (ppm) 7.73 (d, 2 H), 7.39-7.27 (m, 7 H), 5.25 (s, 2 H), 5.02 (s, 2 
H), 4.46 (s,2 H), 4.12 (s, 5 H), 3.97 (s, 2 H), 1.34 (s, 12 H). The spectra are in agreement with 
those reported for this compound.9 
Compound 4, protocol 2. Compound 3 (50.0 mg, 108 µmol) was dissolved in anhydrous DMF (2 
mL) under a nitrogen atmosphere. The solution was treated with NaH (5.20 mg, 130 µmol, 60 % 
mineral oil suspended) and stirred 30 min at 22 °C. Benzyl bromide (27.8 mg, 19.3 µL 163 
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µmol) was added and the reaction was stirred for 2 h at 22 °C. Then, the solvent was removed in 
vacuum (0.01 mbar) and the product was purified by column chromatography on silica gel using 
petroleum ether/acetone (4/1, v/v) as eluent. Yield: 55 mg, 100 µmol (92%).  
Compound 5 was prepared analogously to compound 4 using protocol 1.  The product was 
obtained as orange solid. Yield: 253 mg, 444 µmol (68%). TLC (SiO2, eluent petroleum 
ether/acetone, 4/1, v/v) Rf = 0.5; 1H-NMR (300 MHz, aceton-d6)μ δ (ppm) 7.75 (d, 2H), 7.41 (m, 
3H), 7.19-7.03 (m, 3H), 5.27 (s, 2H), 5.05 (s, 2H), 4.47 (s, 2H), 4.15 (s, 5H), 4.00 (s, 2H), 1.35 
(s, 12H); 13C-NMR (101 MHz, aceton-d6)μ δ (ppm) 164.65, 162.23, 142.57, 140.30, 135.11, 
130.78, 127.47, 122.65, 114.02, 113.81, 113.65, 113.43, 84.08, 69.28, 67.49, 64.68, 62.81, 62.75, 
24.71; HR-MS (ESI +), m/z: calculated for C31H33BFFeNO4 [M-e-]+ 569.1836, found 569.1826; 
C, H, N analysis: calculated for C31H33BFFeNO4 (%) – C 65.41, H 5.84, N 2.46; found – C 
65.39, H 5.96, N 2.56. 
Compound 6 was prepared analogously to compound 4 using protocol 1.  The product was 
obtained as orange oil. Yield: 274 mg, 471 µmol (73%). TLC (SiO2, eluent petroleum 
ether/acetone, 4/1, v/v) Rf = 0.51; 1H-NMR (400 MHz, aceton-d6)μ δ (ppm) 7.75 (d, 2H), 7.4-
7.27 (m, 3H), 6.92-6.84 (m, 3H), 5.27 (s, 2H), 5.00 (s, 2H), 4.47 (s, 2H), 4.14 (s, 5H), 3.99 (s, 
2H), 1.35 (s, 12H); 13C-NMR (101 MHz, aceton-d6)μ δ (ppm) 160.4λ, 155.01, 141.03, 140.41, 
135.14, 129.92, 127.50, 118.84, 112.55, 112.46, 101.79, 84.09, 69.28, 68.86, 67.37, 64.59, 62.82, 
54.98, 53.71, 24.76; HR-MS (ESI+), m/z: calculated for C32H36BFeNO5 [M-e-]+ 518.2036, found 
581.2030; C, H, N analysis: calculated for C32H36BFeNO5 (%) – C 66.12, H 6.24, N 2.41; found 
– C 65.69, H 6.25, N 2.43. 
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Compound 7 was prepared analogously to compound 4 using protocol 1.  The product was 
obtained as orange oil. Yield: 36 mg, 59 µmol (9%). TLC (SiO2, eluent petroleum ether/acetone, 
6/1, v/v)  Rf = 0.29; 1H-NMR (300 MHz, aceton-d6)μ δ (ppm) 7.77 (d, 2 H), 7.37 (m, 4 H), 7.12 
(d, 2 H), 5.27 (s, 2 H),  5.02 (s, 2 H),  4.48 (s, 2 H), 4.14 (s, 5 H),  3.99 (s, 2 H),  2.27 (s, 3 H),  
1.35 (s, 5 H); 13C-NMR (75 MHz, aceton-d6)μ δ (ppm) 168.30, 156.22, 14λ.51, 13λ.47, 135.85, 
134.27, 126.99, 126.76, 121.47, 121.19, 83.20, 69.31, 68.71, 68.44, 68.35, 68.06, 63.73, 23.84, 
19.62; HR-MS (ESI+), m/z: calculated for C33H36BFeNO6 [M-e-]+ 609.1986, found 609.1984; C, 
H, N analysis: calculated for C33H36BFeNO6 (%) – C 65.05, H 5.96, N 2.30; found – C 63.31, H 
6.04, N 2.26. 
Compound 8 was prepared analogously to compound 4 using protocol 1. TLC (SiO2, eluent 
petroleum ether/acetone, 4/1, v/v) Rf = 0.36; 
1
H-NMR (300 MHz, aceton-d6): δ (ppm) 8.57 (d, 
2H), 7.78-7.70 (m, 3 H), 7.3-7.27 (m, 4 H), 5.22 (s, 2 H), 5.07 (s, 2 H), 4.48 (s, 2 H), 4.11 (s, 5 
H), 3.98 (s, 2 H), 1.33 (s, 12 H); HR-MS (ESI+), m/z: calculated for C30H33BFeN2O4 552.1883, 
found 552.1891. 
Compound 9 was prepared analogously to compound 4 using protocol 1. .  The product was 
obtained as orange oil. Yield: 84 mg, 152 µmol (23%). TLC (SiO2, eluent petroleum 
ether/acetone, 4/1, v/v) Rf = 0.35; 1H-NMR (300 MHz, aceton-d6)μ δ (ppm) 8.60 (d, 2H), 8.48 
(dd, 2H) 7.75-7.68 (m, 3 H), 7.38-7.32 (m, 3 H), 5.25 (s, 2 H), 5.05 (s, 2 H), 4.46 (s, 2 H), 4.12 
(s, 5 H), 4.00 (s, 2 H), 1.33 (s, 12 H); 13C-NMR (75 MHz, aceton-d6)μ δ (ppm) 155.28, 14λ.36, 
149.26, 140.72, 135.61, 135.23, 134.85, 128.00 (two overlapping peaks), 124.20, 102.15, 84.57, 
69.77, 68.03, 65.23, 63.25, 52.07, 25.20; HR-MS (ESI+), m/z: calculated for C30H33BFeN2O4 
[M-e-]+ 552.18827, found 552.18783; C, H, N analysis: calculated for C30H33BFeN2O4 (%) – C 
65.25, H 6.02, N 5.07; found – C 65.28, H 5.97, N 5.08. 
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Compound 10. Compound 3 (1.0 g, 2.17 mmol) was dissolved in anhydrous DMF (12 mL) under 
a nitrogen atmosphere. Then Cs2CO3 (4.24 g, 13.01 mmol) and TBAI (4.79, 13.01 mmol) were 
added to the solution. After stirring for 30 minutes at ambient temperature, diphenylmethyl 
chloride (2.31 mL, 2.64 g, 13.01 mmol) was added. The mixture was stirred for 7 days at 22 °C. 
Then, the solvent was removed in vacuum (0.01 mbar) and the product was purified by column 
chromatography on silica gel using DCM - DCM/ethylacetate (4/1, v/v) followed by a second 
column using petroleum ether/acetone (6/1, v/v). The product was isolated as orange solid. 
Yield: 78 mg, 124 µmol (6%). TLC (SiO2, eluent petroleum ether/acetone, 4/1, v/v) Rf = 0.5; 1H-
NMR (400 MHz, aceton-d6)μ δ (ppm) 7.70 (d, 2 H), 7.3λ- 7.30 (m, 2 H), 7.23 (d, 2 H), 6.76 (s, 1 
H), 5.11 (s, 2 H), 4.33 (s, 2 H), 4.10 (s, 5 H), 3.99 (s, 2 H), 1.35 (s, 12 H); 13C-NMR (101 MHz, 
aceton-d6)μ δ (ppm) 154.87, 140.64, 140.24, 135.03, 128.λ5, 128.46, 127.48, 127.44, 126.87, 
102.65, 84.08, 69.46, 69.35, 67.22, 64.73, 64.56, 24.77; HR-MS (ESI+), m/z: calculated for 
C37H38BFeNO4 [M-e-]+ 627.22448, found 627.22496; C, H, N analysis: calculated for 
C37H38BFeNO4 (%) – C 70.84, H 6.11, N 2.23; found – C 70.41, H 6.04, N 2.07. 
Compound 11. Compound 3 (500 mg, 1.08 mmol) was dissolved in anhydrous DMF (25 mL) 
under a nitrogen atmosphere. Then Cs2CO3 (4.24 g, 13.01 mmol) and TBAI (4.79, 13.01 mmol) 
were added to the solution. After stirring for 30 minutes at 22 °C, 1,2-bis(chloromethyl)benzene 
(569 mg, 3.25 mmol) was added. The mixture was stirred for 18 hours at 22 °C. Then, the 
solvent was removed in vacuum (0.01 mbar) and the product was purified by column 
chromatography on silica gel using petroleum ether/acetone (6/1, v/v) as eluent. Further 
purification of the crude orange solid was carried out by recrystallization from aceton. Yield: 222 
mg, 370 µmol (34%). TLC (SiO2, eluent petroleum ether/acetone, 6/1, v/v) Rf = 0.34; 1H-NMR 
(400 MHz, aceton-d6)μ δ (ppm) 7.72 (d, 2 H), 7.50 (d, 1 H), 7.35 (m, 4 H), 7.20 (d, 1 H), 5.28 (s, 
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2 H), 5.25 (s, 2 H), 4.91 (s, 2 H), 4.47 (s, 2 H), 4.19 (s, 5 H), 4.01 (s, 2 H), 1.35 (s, 12 H); 13C-
NMR (101 MHz, CDCl3)μ δ (ppm) 154.24, 138.70, 136.50, 134.80, 134.46, 134.18, 133.25, 
129.99, 128.96, 126.68, 125.01, 83.41, 69.76, 68.76, 67.21, 63.94, 62.14, 50.51, 43.82, 24.43; 
HR-MS (ESI+), m/z: calculated for C32H35BClFeNO4 [M-e-]+ 599.16979, found 599.17064: C, 
H, N analysis: calculated for C32H35BClFeNO4 (%) – C 64.09, H 5.88, N 2.34; found – C 64.19, 
H 5.51, N 2.28. 
Compound 12. Compound 3 (500 mg, 1.08 mmol) was dissolved in anhydrous DMF (5 mL) 
under a nitrogen atmosphere. Then Cs2CO3 (883 mg, 2.71 mmol) and TBAI (799 mg, 
2.17 mmol) were added to the solution. After stirring for 30 minutes at 22 °C, 
1,2-bis(chloromethyl)benzene (114 mg, 651 µmol) was added. The mixture was stirred for 18 
hours at 22 °C. Then, the solvent was removed in vacuum (0.01 mbar) and the product was 
purified by column chromatography on silica gel using petroleum ether/acetone (6/1, v/v) as 
eluent. Yield: 198 mg, 193 µmol (30%). TLC (SiO2, eluent petroleum ether/acetone, 4/1, v/v) Rf 
= 0.32; 1H-NMR (400 MHz, aceton-d6)μ δ (ppm) 7.74 (d, 4 H), 7.29 (m, 8 H), 5.24 (s, 4 H), 5.10 
(s, 4 H), 4.45 (s, 4 H), 4.16 (s, 10 H), 4.00 (s, 4 H), 1.35 (s, 24 H); 13C-NMR (101 MHz, CDCl3): 
δ (ppm) 154.68, 140.35, 135.41, 135.16, 127.2λ, 127.18, 125.66, 102.05, 84.10, 6λ.33, 67.42, 
64.68, 62.91, 51.38, 24.76; HR-MS (ESI+), m/z: calculated for C56H62B2Fe2N2O8 [M-e-]+ 
1024.34051, found 1024.33976; C, H, N analysis: calculated for C56H62B2Fe2N2O8 (%) – C 
65.66, H 6.10, N 2.73; found – C 65.78, H 6.42, N 2.70. 
Compound 14. Compound 139 was dissolved in anhydrous DMF (20 mL) under a nitrogen 
atmosphere. Then Cs2CO3 (1.10 g, 3.40 mmol) and TBAI (1.25 g, 3.40 mmol) were added to the 
solution. After stirring for 30 minutes at 22 °C, benzyl chloride (429 mg, 391 µL, 3.40 mmol) 
was added. The mixture was stirred for 18 hours at 22 °C. Then, the solvent was removed in 
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vacuum (0.01 mbar) and the product was purified by column chromatography on silica gel using 
petroleum ether/acetone (4/1, v/v) as eluent. Yield: 345 mg, 376 µmol (55%). TLC (SiO2, eluent 
petroleum ether/acetone, 4/1, v/v) Rf = 0.46; 1H-NMR (300 MHz, aceton-d6)μ δ (ppm) 7.74 (d, 4 
H), 7.24-7.35 (m, 14 H), 5.27 (s, 4 H), 4.98 (s, 4 H), 4.50 (s, 4 H), 3.95 (s, 4 H), 1.35 (s, 24 H); 
13C-NMR (101 MHz, aceton-d6)μ δ (ppm) = 140.35, 13λ.16, 135.16, 128.82, 128.46, 127.53, 
127.24, 126.87, 126.70, 102.22, 84.08, 67.40, 65.72, 63.49, 53.04, 24.75; HR-MS (ESI+), m/z: 
calculated for C52H58B2FeN2O8 [M-e-]+  916.3740, found 916.3743; C, H, N analysis: calculated 
for C52H58B2FeN2O8 (%) – C 68.15, H 6.38, N 3.06; found – C 68.09, H 6.45, N 3.11. 
Cellular Assays 
Cells and Cell Culture. The human promyelocytic leukemia cell line HL-60 was obtained from 
Sigma-Aldrich (Germany). Burkitt lymphoma cell lines RAJI, BL2 and human mantle cell 
lymphoma cell line JVM-2 were obtained from DSZM (Germany). Cells were cultured 
according to recommendations of DSMZ. In particular, RAJI and JVM-2 cells were grown in 
RPMI 1640 medium supplemented with 10% FBS, 1% L-glutamine, and 1% 
penicillin/streptomycin. BL-2 cells were grown in RPMI 1640 medium supplemented with 20% 
FBS, 1% L-glutamine, and 1% penicillin/streptomycin. All cells studied here are non-adherent. 
Stock suspensions of the cells were grown up to 0.5-1.5 x 106 cells/mL and diluted as required.  
Estimation of oxidative stress in cell cultures. An aliquot of cells was taken from the cultivation 
medium. The medium was replaced with PBS buffer to obtain a cell suspension containing 106 
cells/mL. A solution of 2’,7’-dichlorodihydrofluorescin diacetate (DCFH-DA, 1 ȝL, 5 mM in 
DMSO) was added to the cell suspension (1 mL) and incubated in the dark for 30 min at room 
temperature.  Afterwards, the fluorescence of the samples (Ȝex = 488 nm, Ȝem = 530 nm) was 
determined by using the flow cytometer.  
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Assay for Determination of Cell Permeability of the Prodrugs 
Cells grown in RPMI 1640 medium supplemented with 10% FBS (20% for BL-2), 1% 
glutamine, and 1% penicillin/streptomycin were centrifuged, and the medium was replaced with 
RPMI 1640 medium (5% FCS, 1% L-glutamine, 1% penicillin/streptomycin) to obtain 
suspensions containing 106 cells/mL. Solutions of prodrugs (10 ȝL, solvent DMSO) were added 
to the suspensions (1 mL) and incubated for 1 h. The final concentration of the prodrugs in the 
suspensions was 50 ȝM. Afterwards, cells were washed three times with PBS buffer (3 × 500 
ȝL) and treated with concentrated H2O2 solution (200 ȝL, 1 M) for 30 min, and all volatiles were 
removed by lyophilization. Dry, lysed cells were washed with water (200 ȝL), and aqueous 
solution obtained was acidified with HCl (400 ȝL, 0.1 M). Then this solution was extracted with 
2-ethyl-1,3-hexanediol (100 ȝL, 10% in CHCl3, v/v), and a portion of the organic phase obtained 
(70 ȝL) was mixed with H2SO4/CH3CO2H (400 ȝL, 1/1, v/v). Curcumin solution in methyl 
isobutyl ketone (250 ȝL, 2 mg in 1 mL of the solvent) was added and allowed to react for 2 h. 
The reaction was quenched by addition of water (1 mL). The light absorbance at 550 and 780 nm 
of the organic phase was measured. The former value corresponds to absorbance of curcumin-
boron complex, whereas the second one is taken as a baseline. The baseline corrected absorbance 
at 550 nm (A(550 nm) − A(780 nm)) was proportional to the concentration of boron in the 
mixture.  
Effect of the compounds on the viability of cell lines  
The cells were centrifuged, the medium was removed, and the cells were washed two times with 
PBS buffer and re-suspended in the RPMI 1640 medium containing 5% FBS, 1% L-glutamine, 
and 1% penicillin/streptomycin. This suspension was spread in the wells of a 96-well microtiter 
plate (50 000 cells per well per 100 ȝL). Stock solutions of prodrugs of different concentrations 
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(1 ȝL, solvent DMSO, final concentrations in wells were 1, 5, 10, 20, 50 µM) were added to the 
wells and incubated for 48 h at 37 °C under 5% CO2. Four experiments were conducted for each 
concentration of the prodrug. Finally, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT; 20 ȝL of the solution prepared by dissolving MTT (5 mg) in PBS buffer (1 mL)) 
was added to each well, incubated for 3 h, treated with sodium dodecyl sulfate (SDS) solution 
(λ0 ȝL, 10% solution in 0.01 M aqueous HCl), and incubated overnight. Afterwards, the 
intensity of the absorbance at 590 nm was measured. MTT is converted in live cells to blue dye 
with the absorbance maximum Ȝmax at 590 nm. The absorbance at 690 nm was taken as a 
baseline value.  The baseline corrected absorbance at 590 nm (A(590 nm)-A(690 nm)) was 
applied to calculate the relative number of viable cells. IC50 values were determined by fitting the 
experimental data expressing the number of viable cells (%, OY-axis) versus drug concentration 
(OX-axis) with a sigmoidal curve using a curve fitting system for Windows: CurveExpert 1.4.  
Experiments with primary CLL cells were conducted as described elsewhere.9 The viability of 
CLL cells was determined by ATPlite™ Luminescence Assay System (PerkinElmer, Waltham, 
USA). The cells were incubated in medium containing human serum (HS). TP53 mutation status 
in CLL cells was determined as described elsewhere.
26,27
  
Preparation of rat Precision-Cut Liver Slices (PCLS) and toxicity studies ex vivo. Male Wistar 
rats (Charles River, Sulzfeld, Germany) of 250-450 g were housed under a 12 h dark/light cycle 
at constant humidity and temperature. Animals were permitted free access to tap water and 
standard lab chow. All experiments were approved by the committee for care and use of 
laboratory animals of the University of Groningen and were performed according to strict 
governmental and international guidelines. 
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PCLS were made as described by de Graaf et al.
20
 Cores of tissue (5 mm) were prepared from 
the liver using a coring tool. The slices were prepared with a Krumdieck tissue slicer (Alabama 
R&D, Munford, AL, USA) in ice-cold Krebs-Henseleit buffer saturated with carbogen (95% O2 
and 5% CO2). Liver slices (250 µm thick and 4 mg wet weight) were stored in ice-cold Krebs-
Henseleit buffer until incubation. PCLS were incubated in 12-well plates (Greiner bio-one 
GmbH, Frickenhausen, Austria) at 37°C individually in 1.3 ml Williams’ medium E (WME, 
Gibco by Life Technologies, Paisley, UK) with glutamax-1, supplemented with 25 mM D-
glucose (Gibco) and antibiotics (50 µg/ml gentamicin, Gibco) at pH 7.4 with shaking (90 
times/min) in the atmosphere of carbogen. After 1 h or 24 h of pre-incubation the medium was 
replaced by medium containing the compounds under study. Stock solutions of compounds 4, 15 
and 17 were prepared in dimethyl sulfoxide at a concentration of 10 mM (DMSO, VWR) and 
stored at 4°C. The final concentration of DMSO during the PCLS incubation was always below 
1% to exclude DMSO toxicity. Concentration dependent toxicities of compounds were evaluated 
by incubating the rat PCLS for 24 h with different concentrations of compounds between 0 and 
10 µM. Afterward, the slices were collected for ATP and protein determination, by snap freezing 
them in 1 ml of 70% ethanol/2 mM EDTA. The viability of PCLS was determined by measuring 
the ATP content using the ATP Bioluminescence Assay kit CLS II (Roche, Mannheim, 
Germany) as described previously. The ATP content was corrected by the protein amount of 
each slice and expressed as pmol/µg protein. The protein content of the PCLS was determined by 
the Bio-Rad DC Protein Assay (Munich, Germany), using bovine serum albumin (BSA, Sigma-
Aldrich) for the calibration curve. The ATP data were expressed as the relative value to the 24 h 
control tissue. Obtained values are mean ± SE of at least three independent experiments. 
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In vivo experiments. All experiments were conducted on male mice BDF1 (DBA/2,♀ x C57Bl/6, 
♂) weighing 20-22 g, which were obtained from the vivarium of R. E. Kavetsky Institute of 
Experimental Pathology, Oncology, and Radiobiology of the National Academy of Sciences of 
Ukraine, in agreement with recommendations of the Committee on Bioethics at the Presidium of 
National Academy of Sciences of Ukraine. The prodrug 4 was dissolved in DMSO at 37 °C to 
obtain a 1 mM solution. For obtaining solutions of the required concentration this stock solution 
was diluted with PBS. For determination of the acute toxicity the diluted solutions were 
introduced once via intraperitoneal injections (solution volume 0.5 mL) at doses 10, 50, 100, 
150, 200, 300, 400, 500, 700, 1000, 1500, 3000 and 6000 µg/kg. Each group contained 6 animals 
and was monitored for 3 weeks. Every third day animals were weighted. The weight of animals 
increased by 1.8-2.5 g in both control and treated groups during the time of the experiment. The 
control group received 0.5 mL of the physiological solution (PBS).    
For determination of the antitumor activity the prodrug was introduced intraperitoneally 
everyday (for 6 days) starting from the second day after injection of L1210 cells. The latter cells 
(10
6
 cells/animal) were introduced intraperitoneally. The animals were divided in two groups, 
each containing 15 animals. The first group served as control and received 0.5 mL of the 
physiological solution (PBS). Animals in the other group were treated during 6 days with 
prodrug 4 at a dose of 26 µg/kg per day. 24 h after the last injection of the prodrug solution 
ascites fluid was taken out of animals. In this experimental model ascites fluid contained over 93 
% of L1210 cells with respect to the total cell number.
25
 The integrity of mitochondria (JC-1 
assay, Life Technologies) and the concentration of ROS (CM-H2DCF DA assay, Life 
Technologies) were determined by using flow cytometry (Beckman Coulter, USA, excitation 
laser 488 nm, emission channels: FL1 – 525 nm, FL2 – 575 nm).   
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Measurements of intracellular ROS in L1210 cells: 2.5 × 10
5
 L1210 cells from ascites fluid were 
centrifugated at 1500 rpm for 5 minutes, re-suspended in PBS and incubated for 30 minutes at 37 
°C with CM-H2DCFDA (10 mM). The mean fluorescence of the cells was determined using FL1 
emission channel of the flow cytometer. The acquisition was performed on 10,000 gated events. 
Analysis of mitochondrial transmembrane potential in L1210 cells: JC-1 forms J-aggregates in 
mitochondria of viable cells, which can be detected using FL2 channel. In apoptotic cells green 
monomeric JC-1 remains in the cytosol and can be detected using a FL1 channel. We used the 
ratio of J-aggregates to monomers (FL2 to FL1) as an indicator of the cellular mitochondrial 
transmembrane potential. In particular, L1210 cells (2.5*10
5 
/ mL) were stained with JC-1 (7.5 
mM in PBS) for 10 minutes at 37
0
C. The mean fluorescence of the cells (FL2 and FL1) was then 
determined using a flow cytometer on the basis of the quadrant plot to distinguish monomers 
from J-aggregates. To set the quadrants, in a control experiment the cells were treated with H2O2 
(20 mM, 37 
0
C, 30 minutes) to obtain cells with depolarized mitochondrial membrane potential. 
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